PharmaBlock Sciences (Nanjing) , Inc.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Nanjing Yaoshi Technology Co., Ltd. (abbreviated as Yaoshi Technology, stock code: 300725. SZSE) is an innovative chemical product and service provider in the global pharmaceutical research and development field. The main business includes the research and development, process development, production, and sales of drug molecular blocks; Drug discovery compound library driven by drug molecular blocks; Process research, development, and production services for key intermediates, raw materials, and formulations downstream of drug molecular blocks. Yaoshi Technology has reached partnerships with almost all of the top 20 pharmaceutical companies globally and hundreds of small and medium-sized biotechnology companies to provide them with innovative chemical products and services. The company is always committed to providing better products and services to the market through innovation in chemical and low-carbon technologies in research and development and production processes, helping partners improve the efficiency of new drug discovery and development, and accelerating the project launch process at full speed. Since its establishment, Yaoshi Technology has gained widespread recognition in the industry through years of meticulous cultivation and outstanding design, synthesis, and supply capabilities in the field of pharmaceutical molecular blocks. At present, the company has built a diverse, novel, and high-performance drug molecular block library for global pharmaceutical enterprises. By using and combining these molecular blocks, new drug development enterprises can quickly obtain a large number of candidate compounds for screening and evaluation during the drug discovery phase, and efficiently discover the structure and activity relationships of compounds, ultimately determining clinical candidates, greatly reducing the cycle and economic costs of new drug development. In order to meet the higher-level needs of customers when new drug research and development projects enter the development and commercialization stage, the company continues to expand the types of laboratory level molecular blocks and strengthen the research and production capacity of drug molecular block processes. It has achieved large-scale production and supply of thousands of products. Based on the core resources of molecular blocks, Yaoshi Technology has designed and constructed a variety of new compound libraries, combined with various new drug discovery technologies such as fragment molecular libraries, DNA coding compound libraries, and ultra large capacity characteristic virtual compound library screening, to efficiently obtain all new structures and high drug resistance precursor compounds and lead compounds in multiple fields and different categories of targets, and use this as a carrier to carry out a "risk sharing and benefit sharing" cooperation model. In order to better provide comprehensive and stable high-quality services to customers, the company further expands its business scope and scale, actively creates a high-level one-stop biopharmaceutical CDMO service platform, and provides innovative process research and development of intermediates, raw materials and formulations, production of preclinical and clinical samples, and commercial production services for drug listing for new drug research and development enterprises. Through the team's rich technical, system construction, and production experience, combined with the research and supply advantages accumulated in the field of molecular building blocks, Yaoshi Technology CDMO platform stands out in the industry with its professional chemical capabilities, extensive and stable supply chain resources, unique cost control strategies, and high compliance with quality, EHS, and IP protection systems. In order to further achieve safe, efficient, and green process development and production solutions, Yaoshi Technology has established cutting-edge technology platforms represented by continuous flow chemistry, micro packed bed technology, biocatalysis, metal catalysis, and intelligent manufacturing. The development and application of these innovative technologies have helped many projects solve large-scale production problems, shorten development and production cycles, reduce costs, and bring more long-term value to customers. |
| Headquarter | Nanjing |
| Establish Date | 12/26/2006 |
| Listed Code | 300725.SZ |
| Listed Date | 11/10/2017 |
| Chairman | Yang Minmin. |
| CEO | Yang Minmin. |
| Website | www.pharmablock.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
